MiMedx Group (MDXG) Q2 2024 earnings summary

Executive summary

• Net sales grew 7.3% year-over-year to $87.2 million in Q2 2024, driven by AMNIOEFFECT and EPIEFFECT products, despite commercial headwinds and Medicare reimbursement uncertainty.

• GAAP net income from continuing operations was $18 million, with a net income margin of 20.2%.

• Adjusted EBITDA rose to $20 million (23% of net sales), up from $14 million (17%) last year.

• Launched HELIOGEN, a new bovine-derived xenograft, and initiated a randomized controlled trial for EPIEFFECT.

• Continued investment in clinical research, customer engagement, and digital initiatives, including a new customer portal.

Financial highlights

• Q2 2024 net sales: $87.2 million, up 7.3% year-over-year; gross profit margin was 83.0%.

• Adjusted net income for Q2 2024 was $11.2 million ($0.08/share), up from $5.7 million ($0.03/share) last year.

• Free cash flow for Q2 2024 was $21.7 million, nearly matching all of 2023.

• SG&A expenses were $55 million (64% of sales), up due to commercial and legal costs; R&D was $3 million (3% of sales).

• Cash and cash equivalents were $69 million at quarter end, with no outstanding balance on the revolving credit facility.

Outlook and guidance

• Full-year revenue growth guidance updated to mid- to high-single digits due to Medicare reimbursement disruption.

• Long-term annual net sales growth projected in the low double digits, with adjusted EBITDA margin above 20%.

• Management expects to meet operational liquidity needs for the next twelve months with current cash, operating activities, and available credit.

• Gross margin expected in the low 80s% for the remainder of the year; EBITDA margin to be modestly below 20% in H2.

• Recovery anticipated in Q4 as salesforce and customer churn stabilize.